{"id":"NCT00935532","sponsor":"AstraZeneca","briefTitle":"Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus","officialTitle":"Parallel Group Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus Treated With Oral Antidiabetic(s)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-07","primaryCompletion":"2010-09","completion":"2011-07","firstPosted":"2009-07-09","resultsPosted":"2012-10-24","lastUpdate":"2015-06-15"},"enrollment":427,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"exenatide once weekly","otherNames":[]},{"type":"DRUG","name":"insulin glargine","otherNames":["insulin glargine-Lantus"]}],"arms":[{"label":"exenatide once weekly","type":"EXPERIMENTAL"},{"label":"insulin glargine","type":"ACTIVE_COMPARATOR"}],"summary":"The objectives of this clinical trial are to compare the effects of exenatide once weekly and insulin glargine on blood glucose control, body weight, lipids, safety, and tolerability.","primaryOutcome":{"measure":"Change in HbA1c From Baseline to Endpoint (Week 26)","timeFrame":"Baseline, Week 26","effectByArm":[{"arm":"Exenatide Once Weekly","deltaMin":-1.11,"sd":0.06},{"arm":"Insulin Glargine","deltaMin":-0.68,"sd":0.06}],"pValues":[{"comp":"OG000 vs OG001","p":"<.001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":8},"locations":{"siteCount":22,"countries":["Japan"]},"refs":{"pmids":["32306296","22884767"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":215},"commonTop":["Nasopharyngitis","Injection site induration","Nausea","Constipation","Diarrhoea"]}}